Biomedical Engineering Reference
In-Depth Information
47. Gross, N.,
et al.
, Choroidal neovascularization reduced by targeted drug
delivery with cationic liposome-encapsulated paclitaxel or targeted photo-
dynamic therapy with vertepori n encapsulated in cationic liposomes.
Mol
Vis
, 2013. 19: p. 54-61.
48. Henriksen-Lacey, M.,
et al.
, Liposomal cationic charge and antigen adsorp-
tion are important properties for the ei cient deposition of antigen at the
injection site and ability of the vaccine to induce a CMI response.
J Control
Release
, 2010. 145(2): p. 102-8.
49. Torchilinl, V. and M. Papisov, Why do polyethylene glycol-coated liposomes
circulate so long?: Molecular mechanism of liposome steric protection with
polyethylene glycol: Role of polymer chain l exibility.
J Liposome Res
, 1994.
4(1): p. 725-739.
50. Er, Y.,
et al.
, h e encapsulation and release of guanosine from PEGylated
liposomes.
J Liposome Res
, 2009. 19(1): p. 29-36.
51. Gabizon, A.,
et al.
, h erapeutic ei cacy of a lipid-based prodrug of mitomy-
cin C in pegylated liposomes: studies with human gastro-entero-pancreatic
ectopic tumor models.
J Control Release
, 2012. 160(2): p. 245-53.
52. Grenader, T.,
et al.
, Malignant epithelioid hemangioendothelioma of the
liver successfully treated with pegylated liposomal doxorubicin.
J Clin Oncol
,
2011. 29(25): p. e722-4.
53. Jung, S.H.,
et al.
, Polyethylene glycol-complexed cationic liposome for
enhanced cellular uptake and anticancer activity.
Int J Pharm
, 2009. 382(1-
2): p. 254-61.
54. Kajiwara, E.,
et al.
, Long-circulating liposome-encapsulated ganciclovir
enhances the ei cacy of HSV-TK suicide gene therapy.
J Control Release
,
2007. 120(1-2): p. 104-10.
55. Yang, T.,
et al.
, Enhanced solubility and stability of PEGylated liposomal
paclitaxel: in vitro and in vivo evaluation.
Int J Pharm
, 2007. 338(1-2): p.
317-26.
56. Yang, X.,
et al.
, A novel liposomal formulation of l avopiridol.
Int J Pharm
,
2009. 365(1-2): p. 170-4.
57. Zamboni, W.C.,
et al.
, Plasma, tumor, and tissue disposition of STEALTH
liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bear-
ing A375 human melanoma xenograt s.
Clin Cancer Res
, 2007. 13(23): p.
7217-23.
58. Seetharamu, N.,
et al.
, Phase II study of liposomal cisplatin (SPI-77) in plat-
inum-sensitive recurrences of ovarian cancer.
Anticancer Res
, 2010. 30(2): p.
541-5.
59. Tippayamontri, T.,
et al.
, Cellular uptake and cytoplasm / DNA distribu-
tion of cisplatin and oxaliplatin and their liposomal formulation in human
colorectal cancer cell HCT116.
Invest New Drugs
, 2011. 29(6): p. 1321-7.
60. Hwang,T.,
et al.
, Anticancer Drug-Phospholipid Conjugate for Enhancement
of Intracellular Drug Delivery.
Macromol Symp
, 2007. 249-250(1): p.
109-115.
